Celularity (NASDAQ:CELU) Receives New Coverage from Analysts at HC Wainwright

Stock analysts at HC Wainwright began coverage on shares of Celularity (NASDAQ:CELUGet Rating) in a report released on Wednesday, June 22nd, MarketBeat Ratings reports. The firm set a “buy” rating on the stock.

A number of other research firms have also weighed in on CELU. Truist Financial lowered Celularity from a “buy” rating to a “hold” rating and set a $10.00 target price on the stock. in a report on Wednesday, April 6th. Oppenheimer upped their price objective on shares of Celularity from $9.00 to $10.00 in a report on Friday, April 1st.

NASDAQ CELU traded down $0.44 on Wednesday, hitting $2.79. 64,807 shares of the stock were exchanged, compared to its average volume of 382,228. The company has a market capitalization of $385.89 million, a PE ratio of -1.08 and a beta of -0.37. The business’s fifty day moving average is $7.85 and its 200 day moving average is $6.87. Celularity has a 52 week low of $3.22 and a 52 week high of $13.40.

Celularity (NASDAQ:CELUGet Rating) last issued its earnings results on Monday, May 16th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.25). The firm had revenue of $5.94 million during the quarter, compared to analyst estimates of $5.16 million. Celularity had a negative net margin of 330.93% and a negative return on equity of 136.80%. On average, equities analysts expect that Celularity will post -1.2 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in Celularity in the 3rd quarter valued at $179,000. Marshall Wace LLP acquired a new position in shares of Celularity in the third quarter valued at about $87,000. Verition Fund Management LLC bought a new position in Celularity during the third quarter worth about $354,000. Starr International Co. Inc. bought a new position in Celularity during the fourth quarter worth about $44,240,000. Finally, C V Starr & Co. Inc. acquired a new stake in Celularity in the 4th quarter worth about $22,120,000. Institutional investors own 12.13% of the company’s stock.

Celularity Company Profile (Get Rating)

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.

Read More

Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.